CORE ONE LABS INC - CLABF STOCK NEWS

Core One Labs Inc. (OTC: CLABF) announces that its subsidiary, Vocan Biotechnologies, has successfully tested a proof-of-concept for mass production of biosynthetic N-methyltryptamine (NMT). This advancement utilizes a proprietary Recombinant Production System, promising significant cost reductions for producing psilocybin and analogs while ensuring high efficacy. The team, led by Dr. Hancock, emphasizes the broad potential of their technology in producing psychoactive drugs, with patent protections filed for both processes. Core One aims to revolutionize the psychedelic industry with compliant biosynthetic compounds.

Core One Labs Inc. (OTC: CLABF) has filed a patent application for the production of N-methyltryptamine (NMT) via its optimized recombinant system. This unique process aims to manufacture cGMP-compliant NMT, offering advantages over traditional chemical synthesis by retaining natural stereochemistry. Successful patent approval could allow for rapid, cost-effective mass production of psychedelic compounds, positioning Core One ahead of competitors. The CEO emphasized the importance of this patent for safeguarding intellectual property and diversifying product offerings.

Core One Labs Inc. (OTC: CLABF) announced the completion of its acquisition of Awakened Biosciences Inc., enhancing its portfolio in the psychedelic sector. Awakened specializes in novel technologies for producing synthetic psilocybin, promising scalability and reduced costs. The acquisition includes three provisional patents for advanced production methods. Core One aims to leverage these innovations to generate revenue and expand its catalogue of psychedelic compounds for research. The Transaction involved issuing 7,030,000 shares and 1,458,200 warrants, positioning the company for market growth.

Core One Labs Inc. (OTC: CLABF) announced significant progress in producing API-Grade N-methyltryptamine (NMT), a precursor to DMT. This follows their proprietary recombinant production system that successfully generates psilocybin. With the identification of NMT, Vocan Biotechnologies, a subsidiary of Core One, aims to scale production, bolstering its position in the psychedelic sector. CEO Joel Shacker emphasized that this development could expand Core One's psychedelic product pipeline and enhance its standing in the competitive market.

Core One Labs Inc. (OTC: CLABF) announces progress in developing a novel biosynthetic psilocybin production system via its subsidiary, Vocan Biotechnologies. Following the filing for patent protection, the team has successfully optimized production capacity, which could lower costs and enhance accessibility to psilocybin treatments for mental health disorders.

The patented process utilizes fermentation to produce high-quality psilocybin, positioning Core One as a leading player in the psychedelics market, potentially reshaping mental health care globally.

Core One Labs Inc. (OTC: CLABF) announced a consulting agreement with the Universitat de Barcelona for its subsidiary, Akome Biotech Ltd. This collaboration aims to provide technical guidance for the in vitro development of psychedelic bioactive compounds targeting Major Depressive Disorder, Stroke, Parkinson’s Disease, and Alzheimer’s Disease.

Under the agreement, Professor Maria Carmen Escolano and her team will assist in crucial in vitro studies, which are essential for evaluating the efficacy of new pharmaceutical candidates. This partnership is expected to advance Akome's pipeline for neurodegenerative diseases.

Core One Labs Inc. (OTC: CLABF) announced its subsidiary, Vocan Biotechnologies, has optimized a biosynthetic production system for psilocybin, filing a patent application with the USPTO. This system allows bacteria to produce psilocybin cost-effectively, retaining the natural molecular structure. The patent covers methods for producing cGMP API grade psilocybin, targeting pharmaceutical companies and clinical trials. Dr. Hancock, CEO of Vocan, emphasized that this breakthrough positions Core One as a potential market leader in biosynthetic psychedelics, aiming to enhance mental health treatments.

Core One Labs (OTC: CLABD) has rescheduled its special investor webcast to January 21, 2022, at 1:30 p.m. PST. This adjustment allows Dr. Robert E.W. Hancock and his team from Vocan Biotechnologies to incorporate recent developments into their presentation. Participants can submit questions in advance, and a recording will be available shortly after the live event. Core One focuses on developing psychedelic medications through innovative delivery systems and aims to achieve regulatory approval for its psychedelic-derived treatments, leveraging a significant patient database.

Core One Labs Inc. (CSE: COOL, OTC: CLABD) announced a special investor webcast led by CEO Dr. Robert E.W. Hancock on January 18, 2022, at 1:30 p.m. PST. Participants can submit questions in advance via email. To register for the live event, visit the provided link. A recording will be available on the company’s website post-event. Core One focuses on developing psychedelic medicines and holds a patent-pending technology for delivering these compounds effectively. The company is advancing research for psychedelic-derived treatments for mental health disorders.